Current Report Filing (8-k)
September 24 2018 - 10:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
September 18, 2018
ENDONOVO
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-55453
|
|
45-2552528
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
6320
Canoga Avenue, 15
th
Floor
Woodland
Hills, CA 91367
(Address
of principal executive office)(Zip Code)
Registrant’s
telephone number, including area code:
(800) 489-4774
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
3.03
|
Material
Modification to Rights of Security Holders.
|
On
September 18, 2018, the Registrant filed a certificate of amendment to its certificate of incorporation to increase the number
of shares of common stock which it may issue from 500,000,000 to 2,500,000,000. The amendment was approved by over 60% of the
voting power of the Registrant.
Item
9.01
|
Financial
Statements and Exhibits.
|
|
(a)
|
Financial
Statements -None
|
|
(b)
|
Exhibits
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
September 24, 2018
|
ENDONOVO THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/
Alan Collier
|
|
|
Alan
Collier
|
|
|
Chief
Executive Officer
|